AdvertisementGilead Lobbying Rose As Interest In COVID-19 Treatment ClimbedMay 02, 2020Sydney LupkinfacebookEmailGilead Sciences CEO Daniel O'Day speaks at a meeting with President Trump and members of the White House coronavirus task force on March 2. (AP)
